Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;25(11):1601-8.
doi: 10.3346/jkms.2010.25.11.1601. Epub 2010 Oct 26.

Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor

Jung Sun Cho  1 , Sung-Ho Her, Ju Yeal Baek, Mahn-Won Park, Hyoung Doo Kim, Myung Ho Jeong, Young keun Ahn, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, Chong Jim Kim, Donghoon Choi, Yang Soo Jang, Junghan Yoon, Wook Sung Chung, Jeong Gwan Cho, Ki Bae Seung, Seung Jung Park; Korea Acute Myocardial Infarction Registry Investigators
Collaborators, Affiliations

Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor

Jung Sun Cho et al. J Korean Med Sci. 2010 Nov.

Abstract

The efficacy of low molecular weight heparin (LMWH) with low dose unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) with or without glycoprotein (Gp) IIb/IIIa inhibitor compared to UFH with or without Gp IIb/IIIa inhibitor has not been elucidated. Between October 2005 and July 2007, 2,535 patients with ST elevation acute myocardial infarction (STEMI) undergoing PCI in the Korean Acute Myocardial Infarction Registry (KAMIR) were assigned to either of two groups: a group with Gp IIb/IIIa inhibitor (n=476) or a group without Gp IIb/IIIa inhibitor (n=2,059). These groups were further subdivided according to the use of LMWH with low dose UFH (n=219) or UFH alone (n=257). The primary end points were cardiac death or myocardial infarction during the 30 days after the registration. The primary end point occurred in 4.1% (9/219) of patients managed with LMWH during PCI and Gp IIb/IIIa inhibitor and 10.8% (28/257) of patients managed with UFH and Gp IIb/IIIa inhibitor (odds ratio [OR], 0.290; 95% confidence interval [CI], 0.132-0.634; P=0.006). Thrombolysis In Myocardial Infarction (TIMI) with major bleeding was observed in LMHW and UFH with Gp IIb/IIIa inhibitor (1/219 [0.5%] vs 1/257 [0.4%], P=1.00). For patients with STEMI managed with a primary PCI and Gp IIb/IIIa inhibitor, LMWH is more beneficial than UFH.

Keywords: Blood Platelets; Heparin; Myocardial Infarction; Prognosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart of patients who entered the study. KAMIR, Korean Acute Myocardial Infarction Registry; STEMI, ST-elevation myocardial infarction; LMWH, low molecular weight heparin; PCI, percutaneous coronary intervention; UFH, unfractionated heparin.
Fig. 2
Fig. 2
Concomitant medications during hospitalization. GPI, glycoprotein IIb/IIIa inhibitor; ACE, angiotensin converting enzyme; ARB, aldosterone receptor inhibitor; CCB, calcium channel blocker.
Fig. 3
Fig. 3
Hazard ratio plots of independent predictors with the multivariable analyses for death or myocardial infarction in 30 days in UFH and LMWH groups with glycoprotein IIb/IIIa inhibitor (A) and without glycoprotein IIb/IIIa inhibitor (B) in STEMI patients who underwent primary PCI. *Defined as coronary heart disease in first-degree male relative <55 yr old or coronary heart disease in first-degree female relative <65 yr old. LMWH, low molecular weight heparin; UFH, unfractionated heparin; STEMI, ST-elevation myocardial infarction; PCI, percutaneous coronary intervention.
Fig. 4
Fig. 4
Kaplan-Meier analysis of primary endpoint of UFH and LMWH groups with glycoprotein IIb/IIIa inhibitor (A) and without glycoprotein IIb/IIIa inhibitor (B) in STEMI patients who underwent primary PCI. LMWH, low molecular weight heparin; UFH, unfractionated heparin; STEMI, ST-elevation myocardial infarction; PCI, percutaneous coronary intervention.
See this image and copyright information in PMC

References

    1. Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, López-Sendón J, Laufenberg CV, Klutman M, Gowda N, Gulba D GRACE Investigators. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J. 2005;26:2285–2293. - PubMed
    1. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–54. - PubMed
    1. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ, 3rd, Califf RM. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152:1042–1050. - PubMed
    1. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet. 2001;358:605–613. - PubMed
    1. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, Bogaerts K, Danays T, Lindahl B, Mäkijärvi M, Verheugt F, Van de Werf F. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108:135–142. - PubMed

Publication types

MeSH terms

Substances